Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients

뉴스 본문을 불러오고 있어요.

Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients | 웨이프 WAPE

Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients

기사 요약

관련 종목

댓글 —